BIODESIX INC (BDSX) Stock Price, Quote, News and Overview
NASDAQ:BDSX - Nasdaq - US09075X1081 - Common Stock - Currency: USD
BDSX Quote, Performance and Key Statistics
0.539
-0.03 (-5.64%)
The current stock price of BDSX is 0.539 USD. In the past month the price decreased by -24.38%. In the past year, price decreased by -56.36%.
BDSX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 12.27 | 90.92B | ||
| CVS | CVS HEALTH CORP | 12.05 | 82.46B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.91 | 19.39B | ||
| LH | LABCORP HOLDINGS INC | 15.67 | 19.10B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.22 | 14.35B | ||
| DVA | DAVITA INC | 14.69 | 11.16B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 112.07 | 10.79B | ||
| CHE | CHEMED CORP | 23.58 | 8.12B | ||
| HIMS | HIMS & HERS HEALTH INC | 52.02 | 6.24B | ||
| GH | GUARDANT HEALTH INC | N/A | 5.96B | ||
| CRVL | CORVEL CORP | 26.39 | 5.67B | ||
| OPCH | OPTION CARE HEALTH INC | 26.97 | 5.40B |
Related stock screener links
About BDSX
Company Profile
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 273 full-time employees. The company went IPO on 2020-10-28. The firm develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
Company Info
BIODESIX INC
919 West Dillon Road
Louisville COLORADO US
Employees: 217
Company Website: https://www.biodesix.com/
Investor Relations: https://investors.biodesix.com/
Phone: 13034170500
BIODESIX INC / BDSX FAQ
What is the stock price of BIODESIX INC today?
The current stock price of BDSX is 0.539 USD. The price decreased by -5.64% in the last trading session.
What is the ticker symbol for BIODESIX INC stock?
The exchange symbol of BIODESIX INC is BDSX and it is listed on the Nasdaq exchange.
On which exchange is BDSX stock listed?
BDSX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIODESIX INC stock?
12 analysts have analysed BDSX and the average price target is 3.16 USD. This implies a price increase of 486.64% is expected in the next year compared to the current price of 0.539. Check the BIODESIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIODESIX INC worth?
BIODESIX INC (BDSX) has a market capitalization of 78.68M USD. This makes BDSX a Micro Cap stock.
How many employees does BIODESIX INC have?
BIODESIX INC (BDSX) currently has 217 employees.
What are the support and resistance levels for BIODESIX INC (BDSX) stock?
BIODESIX INC (BDSX) has a resistance level at 0.61. Check the full technical report for a detailed analysis of BDSX support and resistance levels.
Is BIODESIX INC (BDSX) expected to grow?
The Revenue of BIODESIX INC (BDSX) is expected to grow by 31.39% in the next year. Check the estimates tab for more information on the BDSX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIODESIX INC (BDSX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BDSX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BDSX, evaluating the profitability, health, valuation and growth aspects
- BIODESIX INC (BDSX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIODESIX INC (BDSX) Sales and EPS estimates to see what analysts future expectations are.
- BIODESIX INC (BDSX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIODESIX INC (BDSX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIODESIX INC (BDSX) Stock Chart to make your own analysis
- BIODESIX INC (BDSX) Latest news and press-releases to stay up to date.
Does BIODESIX INC (BDSX) stock pay dividends?
BDSX does not pay a dividend.
When does BIODESIX INC (BDSX) report earnings?
BIODESIX INC (BDSX) will report earnings on 2025-05-07, after the market close.
What is the Price/Earnings (PE) ratio of BIODESIX INC (BDSX)?
BIODESIX INC (BDSX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).
What is the Short Interest ratio of BIODESIX INC (BDSX) stock?
The outstanding short interest for BIODESIX INC (BDSX) is 1.7% of its float. Check the ownership tab for more information on the BDSX short interest.
BDSX Technical Analysis
BDSX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BDSX. Both the profitability and financial health of BDSX have multiple concerns.
BDSX Financial Highlights
Over the last trailing twelve months BDSX reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 46.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.15% | ||
| ROE | -205.65% | ||
| Debt/Equity | 1.74 |
BDSX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BDSX. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 39.97% and a revenue growth 31.39% for BDSX